TCR2 Therapeutics Inc.
Compositions and methods for TCR reprogramming using fusion proteins

Last updated:

Abstract:

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Status:
Grant
Type:

Utility

Filling date:

10 Aug 2020

Issue date:

8 Jun 2021